London Daily

Focus on the big picture.
Thursday, Jul 24, 2025

Contraceptive ‘mini pills’ to be offered over the counter in UK

Contraceptive ‘mini pills’ to be offered over the counter in UK

Progesterone pills can be dispensed by pharmacists without prescription from late July, for a charge
Women will be able to buy the contraceptive pill over the counter for the first time in 60 years after a landmark ruling from the UK’s drug regulator.

From the end of July two brands of progesterone-only “mini pills” will be available for as little as under £7.50 a month without a prescription and after a brief consultation with a pharmacist, making them much more accessible to a wider range of women and girls.

The pills contain desogestrel, a synthetic progesterone that inhibits ovulation and prevents fertilisation by thickening the cervical mucus and thinning the uterus lining.

The decision was heralded as “good news for women and families” by June Raine, the chief executive of the Medicines and Healthcare products Regulatory Agency (MHRA).

“Pharmacists have the expertise to advise women on whether desogestrel is an appropriate and safe oral contraceptive pill for them to use and to give women the information they need, to make informed choices,” she said.

However, sexual health doctors called on the government to make the pills free in community pharmacies, since they are available free of charge with a doctor’s prescription, and to make a wider range of brands available.

The two pills, Lovima and Hana, are considered safe for most women to take. Combined oestrogen and progesterone pills, which still require a prescription, carry risks to women who are over 35 and smoke that are considered to potentially outweigh the benefits.

According to Maxwellia, which manufactures Lovima, a month’s supply will cost £10. HRA Pharma, which produces Hana, said it would cost £9.95 for one month and £21.95 for three. The contraceptive pill was first introduced on the NHS in 1961 – but was prescribed only to married women for the first six years.

Research by the Guardian based on freedom of information requests showed that almost nine in 10 women who received contraception from the GP or pharmacies in 2017-18 took the pill. The combined pill was marginally more popular, with 1.7 million women opting for that (55%) and 1.4 million choosing the mini pill (45%).

The MHRA’s decision to reclassify the desogestrel products follows a safety review by the Commission on Human Medicines (CHM) and a public consultation taking in views from patients, pharmacists and doctors.

Edward Morris, the president of the Royal College of Obstetricians and Gynaecologists, said he was delighted that some contraceptive pills would be available in local pharmacies after the college’s years of campaigning against “unnecessary barriers” for women and girls.

He said: “Even before the pandemic, too many women and girls were struggling to access basic women’s health services. The consequences of this include an increase in the number of unplanned pregnancies, which can result in poorer outcomes for women and their babies.”

Robbie Turner, the director of pharmacy at the Royal Pharmaceutical Society, said community pharmacies tended to be more conveniently located, and that pharmacists were well equipped to provide women with expert advice on contraception.

Asha Kasliwal, the president of Faculty of Sexual and Reproductive Healthcare, said she fully supported the reclassification of progesterone-only pills as a pharmacy medicine.

She said: “The fragmented sexual and reproductive healthcare system is notoriously difficult for women to navigate, and successive cuts to public health budgets have made it harder for women to get the contraception they need. Reclassification may also reduce unnecessary pressures on GPs, who will not need to see patients for repeat prescriptions.

“However, reclassification of some brands is only the first step, and buying contraception should definitely not be the only solution. We are calling for these pills to be available to everyone for free in community pharmacies, as well as the reclassification of other contraceptives.”
Newsletter

Related Articles

0:00
0:00
Close
Politic is a good business: Barack Obama’s Reported Net Worth Growth, 1990–2025
Thai Civilian Death Toll Rises to 12 in Cambodian Cross-Border Attacks
TSUNAMI: Trump Just Crossed the Rubicon—And There’s No Turning Back
Over 120 Criminal Cases Dismissed in Boston Amid Public Defender Shortage
UN's Top Court Declares Environmental Protection a Legal Obligation Under International Law
"Crazy Thing": OpenAI's Sam Altman Warns Of AI Voice Fraud Crisis In Banking
The Podcaster Who Accidentally Revealed He Earns Over $10 Million a Year
Trump Announces $550 Billion Japanese Investment and New Trade Agreements with Indonesia and the Philippines
US Treasury Secretary Calls for Institutional Review of Federal Reserve Amid AI‑Driven Growth Expectations
UK Government Considers Dropping Demand for Apple Encryption Backdoor
Severe Flooding in South Korea Claims Lives Amid Ongoing Rescue Operations
Japanese Man Discovers Family Connection Through DNA Testing After Decades of Separation
Russia Signals Openness to Ukraine Peace Talks Amid Escalating Drone Warfare
Switzerland Implements Ban on Mammography Screening
Japanese Prime Minister Vows to Stay After Coalition Loses Upper House Majority
Pogacar Extends Dominance with Stage Fifteen Triumph at Tour de France
CEO Resigns Amid Controversy Over Relationship with HR Executive
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
US Revokes Visas of Brazilian Corrupted Judges Amid Fake Bolsonaro Investigation
U.S. Congress Approves Rescissions Act Cutting Federal Funding for NPR and PBS
North Korea Restricts Foreign Tourist Access to New Seaside Resort
Brazil's Supreme Court Imposes Radical Restrictions on Former President Bolsonaro
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Judge Criticizes DOJ Over Secrecy in Dropping Charges Against Gang Leader
Apple Closes $16.5 Billion Tax Dispute With Ireland
Von der Leyen Faces Setback Over €2 Trillion EU Budget Proposal
UK and Germany Collaborate on Global Military Equipment Sales
Trump Plans Over 10% Tariffs on African and Caribbean Nations
Flying Taxi CEO Reclaims Billionaire Status After Stock Surge
Epstein Files Deepen Republican Party Divide
Zuckerberg Faces $8 Billion Privacy Lawsuit From Meta Shareholders
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
SpaceX Nears $400 Billion Valuation With New Share Sale
Microsoft, US Lab to Use AI for Faster Nuclear Plant Licensing
Trump Walks Back Talk of Firing Fed Chair Jerome Powell
Zelensky Reshuffles Cabinet to Win Support at Home and in Washington
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Irish Tech Worker Detained 100 days by US Authorities for Overstaying Visa
Dimon Warns on Fed Independence as Trump Administration Eyes Powell’s Succession
Church of England Removes 1991 Sexuality Guidelines from Clergy Selection
Superman Franchise Achieves Success with Latest Release
Hungary's Viktor Orban Rejects Agreements on Illegal Migration
Jeff Bezos Considers Purchasing Condé Nast as a Wedding Gift
Ghislaine Maxwell Says She’s Ready to Testify Before Congress on Epstein’s Criminal Empire
Bal des Pompiers: A Celebration of Community and Firefighter Culture in France
FBI Chief Kash Patel Denies Resignation Speculations Amid Epstein List Controversy
Air India Pilot’s Mental Health Records Under Scrutiny
Google Secures Windsurf AI Coding Team in $2.4 Billion Licence Deal
Jamie Dimon Warns Europe Is Losing Global Competitiveness and Flags Market Complacency
×